Contact Information
  • 800-826-HOPE (4673)
Jeffrey N. Weitzel, M.D.
  • Director, Clinical Cancer Genetics
  • Professor
  • Director, Cancer Screening & Prevention Program Network

Languages Spoken
  • French
  • English

Biography

 
Jeffrey Weitzel, M.D. is Chief of the Division of Clinical Cancer Genetics at City of Hope. Dr. Weitzel's multidisciplinary clinical and research program emphasizes the recognition and assessment of people at increased risk for developing cancer because of family cancer history or personal risk factors.

Professional Experience

  • 2007 - present, Professor of Oncology and Population Sciences, City of Hope National Medical Center
  • 2004 - 2007, Associate Professor of Medical Oncology, City of Hope; and Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2007 - present, Clinical Professor of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, CA
  • 1997 - 2007, Clinical Associate Professor of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, CA
  • 1996 - present, Member, City of Hope Cancer Center, Duarte, CA
  • 1996 - present, Chief, Division of Clinical Cancer Genetics and Director, Cancer Screening & Prevention Program, City of Hope; and Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 1996 - present, Staff Physician, Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA
  • 1994 - 1996, Director, Familial Cancer Clinic, New England Medical Center, Boston, MA
  • 1994 - 1996, Fellow in Clinical Genetics, Tufts Univ. School of Medicine, New England Medical Center, Boston, MA
  • 1992 - 1996, Assistant Professor, Departments of Medicine and Obstetrics & Gynecology, Tufts University School of Medicine, Boston, MA
  • 1988 - 1992, Instructor, Department of Medicine, Tufts University School of Medicine, Boston, MA
  • 1987 - 1990, Fellow in Hematology-Oncology, Tufts University School of Medicine, Division of Hematology- Oncology, New England Medical Center Hospitals, Boston, MA
  • 1986 - 1987, Research Fellow, Royal Postgraduate Medical School, Department of Haematology, Hammersmith Hospital, London, U.K.

Education

Education/Training
  • 1983 - 1986, University of Minnesota Hospitals and Clinics, Mpls, MN, Resident in Internal Medicine
  • 1983, University of Minnesota Medical School, Mpls, MN, M.D., Medicine
  • 1979, University of Minnesota, Mpls, MN, B.S., Microbiology

Board Certifications/Licensure
  • 1996, Diplomate American Board of Medical Genetics; Subspecialty Clinical Genetics
  • 1990, Diplomate Subspecialty Hematology
  • 1989, Diplomate Subspecialty Medical Oncology
  • 1986, Diplomate American Board of Internal Medicine
  • 1984, Diplomate of the National Board of Medical Examiners

Memberships

  • 2005 - 2007, Editorial Board, Journal of Clinical Oncology
  • 1998 - 2006, NCI Scientific Review Group Subcommittee G
  • 1998, National Surgical Adjuvant Breast and Bowel Project
  • 1998, Editorial Board, Breast Diseases: A Year Book Quarterly
  • 1998 - present, American Society of Clinical Oncology
  • 1997, Southwest Oncology Group; Cancer Control and Breast Cancer Committees
  • 1997 - 2003, Task Force on Cancer Genetics Education for the American Society of Clinical Oncology
  • 1994 - present, American Society of Human Genetics
  • 1993 - 1996, Medical Research Committee, American Cancer Society (Massachusetts Chapter)
  • 1993 - 1996, Gynecologic Oncology Group, Applied Science and Tumor Biology Committee
  • 1990, American Association for Cancer Research

Publications

1. Weitzel, JN, Hows, JM, Jeffreys, AJ, Min, GL, & Goldman, JM. (1988). Use of a hypervariable minisatellite DNA probe (33.15) for evaluating engraftment two or more years after bone marrow transplantation for severe aplastic anemia. Brit J Haematol, 70: 91-97.
 
2. Weitzel, JN, Pooler, PA, Mohammed, R, Levitt, MD, & Eckfeldt, JH. (1988). A Unique Case of Breast Carcinoma Producing Pancreatic-type Isoamylase. Gastroenterology, 94: 519-520.
 
3. Weitzel, JN, Sadowski, J, Furie, BC, Moroose, R, Kim, H, Mount, ME, Murphy, MJ, & Furie, B. (1990). Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: Clinical and metabolic studies of three cases. Blood, 76: 2555-2559.

4. Weitzel, JN, Kasperczyk, Mohan, C, & Krontiris, TG. (1992). The HRAS1 gene cluster: Two upstream regions recognizing transcripts and a third encoding a gene with a leucine zipper domain. Genomics, 14: 309-319.

5. Carroll, JC, Quinn, CC, Weitzel, JN, & Sant, GR. (1994). Metastatic renal cell carcinoma to the right cardiac ventricle without contiguous vene caval involvement. J Urology, 151: 133-134.

6. Weitzel, JN, & Patel, J. (1994). A single P1 clone bearing three genes from human chromosome 11p15.5; HRC1, HRAS1, and RNH. Genetic Analysis: Techniques and Applications, 11: 165-170.

7. Weitzel, JN, Patel, J, Smith, DM, Goodman, A, Safaii, H, & Ball, HG. (1994). Molecular genetic changes associated with ovarian cancer. Gynecol Oncol, 55: 245-252.

8. Mark, HFL, Annas, G, Ricker, R, & Weitzel, JN. (1996). Clinical and research issues in breast cancer genetics. Ann Clin Lab Sci, 26: 396-408.

9. Weitzel, JN. (1996). Genetic counseling for familial cancer risk. Hosp Pract, 31: 57-69.

10. Grendys, EC, Jr, Barnes, WA, Weitzel, JN, Sparkowski, J, & Schlegel, R. (1997). Identification of H, K, and N-ras point mutations in stage IB cervical carcinoma. Gynecol Oncol, 65: 343-347.

11. Lu, KH, Weitzel, JN, Kodali, S, Welch, WR, Berkowitz, RS, & Mok, SC. (1997). A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res, 57: 387-390.

12. Choi, S-W, Kim, Y-I, Weitzel, JN, & Mason, JB. (1998). Folate depletion impairs DNA excision repair in the colon of the rat. Gut, 43: 93-99.

13. Weitzel, JN. (1998). The crystal ball of genetic cancer risk assessment: Who wouldn't want to know their future? Ann Surg Oncol, 5: 567-568.

14. Weitzel, JN, & MacDonald, DJ. (1998). Genetic testing for ovarian cancer risk. Quality of Life-A Nursing Challenge, 6: 101-108.

15. Weitzel, JN. (1999). The current social, political, and medical role of genetic testing in familial breast and ovarian carcinomas. Curr Opin Obstet Gyn, 11: 65-70.

16. Weitzel, JN. (1999). Genetic cancer risk assessment: Putting it all together. Cancer, 86(11 Suppl): 2483-2492.

17. Weitzel, JN. (2000). Clinical applications of genetics: Hereditary breast and ovarian carcinoma. Oncologia Clinica, 5(3): 409-417.

18. Weitzel, JN, Ding, S, Larson, GP, Nelson, RA, Goodman, A, Grendys, EC, Ball, HG, & Krontiris, TG. (2000). The HRAS1 minisatellite locus and risk of ovarian cancer. Cancer Res, 60: 259-261.

19. Weitzel, JN, & McCahill, LE. (2001). The power of genetics to target surgical prevention. New Engl J Med, 344: 1942-1944.

20. Blazer, KR, Grant, M, Sand, SR, MacDonald, DJ, Choi, JJ, Nedelcu, RA, & Weitzel, JN. (2002). Development of a cancer genetics education program for clinicians. J Cancer Educ, 17: 69-73.

21. Foulkes, WD, Thiffault, I, Gruber, SB, Horwitz, M, Hamel, N, Lee, C, Shia, J, Markowitz, A, Figer, A, Friedman, E, Farber, D, Greenwood, CM, Bonner, JD, Nafa, K, Walsh, T, Marcus, V, Tomsho, L, Gebert, J, Macrae, FA, Gaff, CL, Paillerets, BB, Gregersen, PK, Weitzel, JN, Gordon, PH, MacNamara, E, King, MC, Hampel, H, De La Chapelle, A, Boyd, J, Offit, K, Rennert, G, Chong, G, & Ellis, NA. (2002). The Founder Mutation MSH2*1906G-->C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population. Am J Hum Genet, 71(6): 1395-1412.

22. Herzog, JS, Jancis, EM, Liao, S, Somlo, G, & Weitzel, JN. (2002). Restriction endonuclease fingerprinting enhanced conformation sensitive gel electrophoresis (REF-CSGE) in the analysis of BRCA1 exon 11 mutations in a high-risk breast cancer cohort. Hum Mutat, 19: 656-663.

23. MacDonald, DJ, Choi, J, Ferrell, B, Sand, S, McCaffrey, S, Blazer, KR, Grant, M, & Weitzel, JN. (2002). Concerns of women presenting to a comprehensive cancer center for genetic cancer risk assessment. J Med Genet, 39: 526-530.

24. Narod, SA, Dube, MP, Klijn, J, Lubinski, J, Lynch, HT, Ghadirian, P, Provencher, D, Heimdal, K, Moller, P, Robson, M, Offit, K, Isaacs, C, Weber, B, Friedman, E, Gershoni-Baruch, R, Rennert, G, Pasini, B, Wagner, T, Daly, M, Garber, JE, Neuhausen, SL, Ainsworth, P, Olsson, H, Evans, G, Osborne, M, Couch, F, Foulkes, WD, Warner, E, Kim-Sing, C, Olopade, O, Tung, N, Saal, HM, Weitzel, JN, Merajver, S, Gauthier-Villars, M, Jernstrom, H, Sun, P, & Brunet, JS. (2002). Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 carriers. J Natl Cancer I, 94(23): 1773-1779.

25. Solano, AR, Dourisboure, RJ, Weitzel, JN, & Podesta, EJ. (2002). A cautionary note: false homozygosity for BRCA2 6174delT mutation resulting from a single nucleotide polymorphism masking the wt allele. Eur J Hum Genet, 10(6): 395-397.

26. Cullinane, CA, Ellenhorn, JDI, & Weitzel, JN. (2003). Microsatellite instability is a rare finding in the tumors of patients with both primary renal and rectal neoplasms. Cancer Genet Cytogen, 148(2): 163-165.

27. Loo, JC, Liu, L, Hao, A, Gao, L, Agatep, R, Shennan, M, Summers, A, Goldstein, AM, Tucker, MA, Deters, C, Fusaro, R, Blazer, K, Weitzel, JN, Lassam, N, Lynch, H, & Hogg, D. (2003). Germline splicing mutations of CDKN2A predispose to melanoma. Oncogene, 22(41): 6387-6394.

28. Weitzel, JN, McCaffrey, SM, Nedelcu, R, MacDonald, DJ, Blazer, KR, & Cullinane, CA. (2003). Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg-Chicago, 138(12): 1323-1328; discussion 1329.

29. Blazer, KR, Grant, M, Sand, SR, MacDonald, DJ, Uman, GC, & Weitzel, JN. (2004). Effects of a cancer genetics education programme on clinicians knowledge and practice. J Med Genet, 41(7): 518-522.

30. Brenner, RJ, Weitzel, JN, Hansen, N, & Boasberg, P. (2004). Screening detected breast cancer in a man with BRCA2 mutation: Case Report. Radiology, 230(2): 553-555.

31. Martinez, SL, Herzog, J, & Weitzel, JN. (2004). Loss of five amino acids in BRCA2 is associated with ovarian cancer. J Med Genet, 41(2): e18.

32. Nedelcu, R, Blazer, KR, Schwerin, BU, Gambol, P, Mantha, P, Uman, GC, & Weitzel, JN. (2004). Genetic discrimination: the clinician perspective. Clin Genet, 66(4): 311-317.

33. Somlo, G, Frankel, P, Chow, W, Leong, L, Margolin, K, Morgan, R, Jr, Shibata, S, Chu, P, Forman, S, Lim, D, Twardowski, P, Weitzel, JN, Alvarnas, J, Kogut, N, Schriber, J, Fermin, E, Yen, Y, Damon, L, & Doroshow, JH. (2004). Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol, 22(10): 1839-1848.

34. Weitzel, JN. (2004). Evidence for Advice: Reduction in Risk of Breast or Ovarian Cancer After Salpingo-Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations. Breast Diseases: A Year Book Quarterly, 14(4): 354-356.

35. Blazer, KR, MacDonald, DJ, Ricker, C, Sand, S, Uman, GC, & Weitzel, JN. (2005). Outcomes from intensive training in genetic cancer risk counseling for clinicians. Genet Med, 7(1): 40-47.

36. Cullinane, CA, Lubinski, J, Neuhausen, SL, Ghadirian, P, Lynch, HT, Isaacs, C, Weber, B, Moller, P, Offit, K, Kim-Sing, C, Friedman, E, Randall, S, Pasini, B, Ainsworth, P, Gershoni-Baruch, R, Foulkes, WD, Klijn, J, Tung, N, Rennert, G, Olopade, O, Couch, F, Wagner, T, Olsson, H, Sun, P, Weitzel, JN, & Narod, S. (2005). The effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer, 117(6): 988-991.

37. Larson, GP, Ding, Y, Cheng, LS, Lundberg, C, Gagalang, V, Guillermo, R, Geller, LN, Weitzel, JN, MacDonald, D, Archambeau, J, Slater, J, Neuberg, D, Daly, MB, Angel, I, Benson, IAB, Smith, K, Kirkwood, JM, O’Dwyer, PJ, Raskay, B, Sutphen, R, Drew, R, Stewart, JA, Werndli, J, Johnson, D, Ruckdeschel, JC, Elston, RC, & Krontiris, TG. (2005). Genetic Linkage of Prostate Cancer Risk to the Chromosome 3 Region Bearing FHIT. Cancer Res, 65(3): 805-814.

38. Culver, J. O., Edwards, Q. T., MacDonald, D. J., & Weitzel, JN (2005). USPSTF guidelines will miss BRCA families due to paternal inheritance or a truncated family tree. Ann Intern Med, 143(5), 355. Retrieved from http://www.annals.org/content/143/5/355.abstract/reply# nnintmed_el_2247

39. MacDonald, DJ, Sarna, L, Uman, GC, Grant, M, & Weitzel, JN. (2005). Health beliefs of women with and without breast cancer seeking genetic cancer risk assessment. Cancer Nurs, 28(5): 372-379.

40. Palomares, MR, Paz, IB, & Weitzel, JN. (2005). Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice. J Clin Oncol, 23(13): 3165-3166.

41. Sand, SR, DeRam, DS, MacDonald, DJ, Blazer, KR, & Weitzel, JN. (2005). Linkage of a pedigree drawing program and database to a program for determining BRCA mutation carrier probability. Fam Cancer, 4(4): 313-316.

42. Weitzel, JN, Lagos, V, Blazer, KR, Nelson, R, Ricker, C, Herzog, J, McGuire, C, & Neuhausen, S. (2005). Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidem Biomar, 14: 1666-1671.

43. Weitzel, JN, Robson, M, Pasini, B, Manoukian, S, Stoppa-Lyoneet, D, Lynch, HT, McLennan, J, Foulkes, WD, Wagner, T, Tung, N, Ghadirian, P, Olopade, O, Isaacs, C, Kim-Sing, C, Møller, P, Neuhausen, SL, Metcalfe, K, Sun, P, & Narod, SA. (2005). A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidem Biomar, 14(6): 1534-1538.

44. Blazer, KR, MacDonald, DJ, Justus, KA, Grant, M, Azen, SP, Chamberlain, RM, Petersen, GM, King, M, & Weitzel, JN. (2006). Creating Tomorrow's Leaders in Cancer Prevention: A Novel Interdisciplinary Career Development Program in Cancer Genetics Research. J Cancer Educ, 21(4): 216-222.

45. Finch, A, Beiner, M, Lubinski, J, Lynch, HT, Moller, P, Rosen, B, Murphy, J, Ghadirian, P, Friedman, E, Foulkes, WD, Kim-Sing, C, Wagner, T, Tung, N, Couch, F, Stoppa-Lyonnet, D, Ainsworth, P, Daly, M, Pasini, B, Gershoni-Baruch, R, Eng, C, Olopade, OI, McLennan, J, Karlan, B, Weitzel, JN, Sun, P, & Narod, SA, for the Hereditary Ovarian Cancer Clinical Study Group. (2006). Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation. JAMA-J Am Med Assoc, 296(2): 185-192.

46. Gronwald, J, Tung, N, Foulkes, WD, Offit, K, Gershoni, R, Daly, M, Kim-Sing, C, Olsson, H, Ainsworth, P, Eisen, A, Saal, H, Friedman, E, Olopade, O, Osborne, M, Weitzel, JN, Lynch, H, Ghadirian, P, Lubinski, J, Sun, P, & Narod, SA. (2006). Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer, 118(9): 2281-2284.

47. Guillem, JG, Wood, WC, Moley, JF, Berchuck, A, Karlan, BY, Mutch, DG, Gagel, RF, Weitzel, JN, Morrow, M, Weber, BL, Giardiello, F, Rodriguez-Bigas, MA, Church, J, Gruber, S, & Offit, K. (2006). ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol, 24(28): 4642-4660.

48. Guillem, JG, Wood, WC, Moley, JF, Berchuck, A, Karlan, BY, Mutch, DG, Gagel, RF, Weitzel, JN, Morrow, M, Weber, BL, Giardiello, F, Rodriguez-Bigas, MA, Church, J, Gruber, S, & Offit, K. (2006). ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol, 13(10): 1296-1321.

49. Jasperson, KW, Lowstuter, K, & Weitzel, JN. (2006). Assessing the Predictive Accuracy of hMLH1 and hMSH2 Mutation Probability Models. J Genet Couns, 15(5): 339-347.

50. MacDonald, DJ, Sarna, L, Uman, GC, Grant, M, & Weitzel, JN. (2006). Cancer screening and risk reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers. Oncol Nurs Forum, 33(2): E27-E35.

51. MacDonald, DJ, Sand, S, Kass, FC, Blazer, KR, Congleton, J, Craig, J, & Weitzel, JN. (2006). The power of partnership: Extending comprehensive cancer center expertise in clinical cancer genetics to breast care in community centers. Semin Breast Dis, 9: 39-47.

52. Ricker, C, Lagos, V, Feldman, N, Hiyama, S, Fuentes, S, Kumar, V, Gonzalez, K, Palomares, M, Blazer, K, Lowstuter, K, Macdonald, D, & Weitzel, JN. (2006). If we build it…will they come?--establishing a cancer genetics services clinic for an underserved predominantly Latina cohort.  J Genet Couns, 15(6): 505-514.

53. Antoniou, AC, Sinilnikova, OM, Simard, J, Léoné, M, Dumont, M, Neuhausen, SL, Struewing, JP, Stoppa-Lyonnet, D, Barjhoux, L, Hughes, DJ, Coupier, I, Belotti, M, Lasset, C, Bonadona, V, Bignon, YJ, Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), Rebbeck, TR, Wagner, T, Lynch, HT, Domchek, SM, Nathanson, KL, Garber, JE, Weitzel, JN, Narod, SA, Tomlinson, G, Olopade, OI, Godwin, A, Isaacs, C, Jakubowska, A, Lubinski, J, Gronwald, J, Górski, B, Byrski, T, Huzarski, T, Peock, S, Cook, M, Baynes, C, Murray, A, Rogers, M, Daly, PA, Dorkins, HEpidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), Schmutzler, RK, Versmold, B, Engel, C, Meindl, A, Arnold, N, Niederacher, D, Deissler, H, German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC), Spurdle, AB, Chen, X, Waddell, N, Cloonan, N, The Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Kirchhoff, T, Offit, K, Friedman, E, Kaufmann, B, Laitman, Y, Galore, G, Rennert, G, Lejbkowicz, F, Raskin, L, Andrulis, IL, Ilyushik, E,Ozcelik, H, Devilee, P, Vreeswijk, MPG, Greene, MH, Prindiville, SA, Osorio, A, Benitez, J, Zikan, M, Szabo, CI, Kilpivaara, O, Nevanlinna, H, Hamann, U, Durocher, F, Arason, A, Couch, FJ, Easton, DF& Chenevix-Trench, G., on behalf of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). (2007). RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet, 81(6): 1186-1200. PMCID: PMC2276351.

54. Couch, FJ, Sinilnikova, O, Vierkant, RA, Pankratz, VS, Fredericksen, ZS, Stoppa-Lyonnet, D, Coupier, I, Hughes, D, Hardouin, A, Berthet, P, GEMO, Peock, S, Cook, M, Baynes, C, Hodgson, S, Morrison, PJ, Porteous, ME, EMBRACE, Jakubowska, A, Lubinski, J, Gronwald, J, Spurdle, AB, kConFab, Schmutzler, R, Versmold, B, Engel, C, Meindl, A, Sutter, C, Horst, J, Schaefer, D, Offit, K, Kirchhoff, T, Andrulis, IL, Ilyushik, E, Glendon, G, Devilee, P, Vreeswijk, MPG, Vasen, HFA, Borg, A, Backenhorn, K, Struewing, JP, Greene, MH, Neuhausen, SL, Rebbeck, TR, Nathanson, K, Domchek, S, Wagner, T, Garber, JE, Szabo, C, Zikan, M, Foretova, L, Olson, JE, Sellers, TA, Lindor, N, Nevanlinna, H, Tommiska, J, Aittomaki, K, Hamann, U, Rashid, MU, Torres, D, Simard, J, Durocher, F, Guenard, F, INHERIT BRCAs, Lynch, HT, Isaacs, C, Weitzel, JN, Olopade, OI, Narod, S, Daly, MB, Godwin, AK, Tomlinson, G, Easton, DF, Chenevix-Trench, G, & Antoniou, AC. (2007). AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A CIMBA study. Cancer Epidem Biomar, 16(7): 1416-1421.

55. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B,Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel JN, Sun P, & Narod SA, for the Hereditary Ovarian Cancer Clinical Study Group. (2007) Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women with a BRCA1 or BRCA2 Mutation. Obstet Gynecol Surv, 62:29-31.

56. Friebel, TM, Domchek, SM, Neuhausen, SL, Wagner, T, Evans, DG, Isaacs, C, Garber, JE, Daly, MB, Eeles, R, Matloff, E, Tomlinson, G, Lynch, HT, Tung, N, Blum, JL, Weitzel, JN, Rubinstein, WS, Ganz, PA, Couch, F, & Rebbeck, TR (2007). Bilateral Prophylactic Oophorectomy and Bilateral Prophylactic Mastectomy in a Prospective Cohort of Unaffected BRCA1 and BRCA2 Mutation Carriers. Clin Breast Cancer, 7(11): 875-882.

57. Kotsopoulos, J, Lubinski, J, Lynch, HT, Klijn, J, Ghadirian, P, Neuhausen, SL, Kim-Sing, C, Foulkes, WD, Moller, P, Isaacs, C, Domchek, S, Randall, S, Offit, K, Tung, N, Ainsworth, P, Gershoni-Baruch, R, Eisen, A, Daly, M, Karlan, B, Saal, HM, Couch, F, Pasini, B, Wagner, T, Friedman, E, Rennert, G, Eng, C, Weitzel, JN, Sun, P, & Narod, SA. (2007). Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat, 105: 221-228.

58. MacDonald, DJ, Sarna, L, van Servellen, G, Bastani, R, Giger, JN, & Weitzel, JN. (2007). Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet Med, 9(5): 275-282

59. Parmigiani, G, Chen, S, Iversen, ES, Kligner, TM, Finkelstein, D, Anton-Culver, H, Ziogas, A, Weber, BL, Eisen, A, Malone, KE, Daling, JR, Hsu, L, Ostrander, EA, Peterson, LE, Schildkraut, JM, Isaacs, C, Corio, C, Leondaridis, L, Tomlinson, G, Amos, CI, Strong, LC, Berry, DA, Weitzel, JN, Sand, S, Dutson, D, Kerber, R, Peshkin, BN, & Euhus, DM. (2007). Validity of models for prediction of BRCA1 and BRCA2 mutations. Ann Intern Med, 147(7): 441-450.

60. Ricker, CN, Hiyama, S, Fuentes, S, Feldman, N, Kumar, V, Uman, GC, Nedelcu, R, Blazer, KR, MacDonald, DJ, & Weitzel, JN. (2007). Beliefs and Interest in Cancer Risk in an Underserved Latino Cohort. Prev Med, 44(3): 241-245.

61. Weitzel, JN, Buys, SS, Sherman, WH, Daniels, AM, Ursin, G, Daniels, JR, MacDonald, DJ, Blazer, KR, Pike, MC, & Spicer, DV. (2007). Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonist-Based Chemoprevention Regimen in BRCA1 Carriers. Clin Cancer Res, 13(2): 654-658.

62. Weitzel, JN, Lagos, VI, Cullinane, CA, Gambol, PJ, Culver, JO, Blazer, KR, Palomares, MR, Lowstuter, KJ, & MacDonald, DJ. (2007). Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA-J Am Med Assoc, 297(23): 2587-2595

63. Weitzel, JN, Lagos, VI, Herzog, JS, Judkins, T, Hendrickson, B, Ho, JS, Ricker, CN, Lowstuter, KJ, Blazer, KR, Tomlinson, G, & Scholl, T. (2007). Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidem Biomar, 16(8): 1615-1620.

64. Antoniou, AC, Spurdle, AB, Healey, S, Pooley, KA, Schmutzler, RK,Versmold, B, Engel, C,, Meindl, A, Arnold, N, Hofmann, W, Sutter, C, Niederacher, D, Deissler, H, Caldes, T, Kämpjärvi, K, Nevanlinna, H, Simard, J, Beesley, J, Chen, X, Neuhausen, SL, Rebbeck, TR, Wagner, T, Lynch, HT, Isaacs, C, Weitzel, JN, Ganz, PA, Daly, MB, Tomlinson, G, Olopade, OI, Blum, JL, Couch, FJ, Peterlongo, P, Manoukian, S, Barile, M, Radice, P, Szabo, CI, Pereira, LHM, Greene, MH, Rennert, G, Lejbkowicz, F, Barnett-Griness, O, Andrulis, IL, Ozcelik, H, Gerdes, A-M, Caligo, MA, Laitman, Y, Kaufman, B, Milgrom, R,Friedman, E, Domchek, SM, Nathanson, KL, Osorio, A, Llort, G, Milne, RL, Benítez, J, Hamann, U, Hogervorst, FBL, Manders, P, Ligtenberg, MJL, Van den Ouweland, AMW, Peock, S, Cook, M, Platte, R, Evans, DG, Eeles, R, Pichert, G, Chu, C, Eccles, D, Davidson, R, Douglas, F, Godwin, AK, Barjhoux, L, Mazoyer, S, Sobol, H, Bourdon, V, Eisinger, F, Chompret, A, Capoulade, C, Bressac-de Paillerets, B, Lenoir, GM, Gauthier-Villars, M, Houdayer, C, Stoppa-Lyonnet,G, Chenevix-Trench,G, & Easton, DF. (2008). Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Am J Hum Genet, 82: 937-948. PMCID: PMC2427217.

65. Jasperson K, Blazer K, Lowstuter K, & Weitzel JN. (2008). Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation. Fam Cancer, 7: 281-285

66. Lagos, VI, Perez, MA, Ricker, CN, Blazer, KR, Santiago, NM, Feldman, N, Viveros, L, & Weitzel, JN. (2008). Social cognitive aspects of underserved Latinas preparing to undergo genetic risk assessment for hereditary breast and ovarian cancer. Psycho-Oncology, 17(8): 774-782

67. Lowstuter, KJ, Sand, SR, Blazer, KR, MacDonald, DJ, Banks, KC, Lee, CA, Schwerin, BU, Juarez, M, Uman, GC, & Weitzel, JN. (2008). Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med, 10(9): 691-698

68. MacDonald, DJ, Sarna, L, Giger, JN, Bastani, R, van Servellen, G, & Weitzel, JN. (2008) Comparison of Latina and non-Latina White women’s beliefs about communicating genetic cancer risk to relatives. J Health Commun, 13(5): 465-479

69. Mai, PL, Lagos, VI, Palomares, MR, & Weitzel, JN. (2008). Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. A Surg Oncol, 15: 3415-3421. PMCID: PMC2993252

70. Maradiegue, A, Jasperson, K, Edwards, QT, Lowstuter, K, & Weitzel, JN. (2008). Scoping the family history: Assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings-A primer for nurse practitioners. J Am Acad Nurse Prac, 20: 76-84

71. Metcalfe, KA, Lubinski, J, Ghadirian, P, Lynch, H, Kim-Sing, C, Friedman, E, Foulkes, WD, Domchek, S, Ainsworth, P, Isaacs, C, Tung, N, Gronwald, J, Cummings, S, Wagner, T, Manoukian, S, Moller, P, Weitzel, JN, Sun, P, & Narod, SA. (2008). Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol, 26: 1093-1097

72. Narod, S. A., Neuhausen, S.L, Vichodez, G., Armel, S., Lynch, H. T., Ghadirian,  P., Cummings, S., Olopade, O., Stoppa-Lyonnet, D. Couch, F. Wagner, T. Warner, E., Foulkes, W. D., Saal, H., Weitzel, JN, Tulman, A., Poll, A., Nam, R., Sun, P., Danquah, J., Domchek, S., Tung, N., Ainsworth, P., Horsman, D., Kim-Sing, C., Maugard, C., Eisen, A., Daly, M., McKinnon, W., Wood, M., Isaacs, C., Gilchrist, D., Karlan, B., Nedelcu, R., Meschino, W., Garber, J., Pasini, B., Manoukian, S., Bellati, C. (2008). Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer, 99(2), 371-374. PMCID: PMC2480973.

73. West, JG, Weitzel, JN, Tao, ML, Carpenter, M, West, JE, & Fanning, C. (2008). BRCA Mutations and the Risk of Angiosarcoma After Breast Cancer Treatment. Clin Breast Cancer, 8: 533-537.

74. Gonzalez, KD, Noltner, KA, Buzin, CH, Gu, D, Wen-Fong, CY, Nguyen, VQ, Han, JH, Lowstuter, K, Longmate, J, Sommer, SS, & Weitzel, JN. (2009). Beyond Li–Fraumeni Syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol, 27: 1250-1256.

75. McKinnon, W., Banks, K.C., Skelly, J., Kohlmann, W., Bennett, R., Shannon, K., Larson-Haidle, J., Ashakaga, T., Weitzel, JN, & Wood, M. (2009). Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals. Fam Cancer, 8: 363-369. PMCID: PMC3528358

76. Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel JN, Narod SA, Ganz PA, Daly MB, Godwin AK, Isaacs C, Olopade OI, Tomlinson G, Rubinstein WS, Tung N, Blum JL, & Gillen DL. (2009). Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res, 11: R76. PMCID: PMC2790858.

77. Pal, SK, Blazer, K, Weitzel, JN, & Somlo, G. (2009). An association between invasive breast cancer and familial idiopathic hyperparathyroidism: A case series and review of the literature. Breast Cancer Res Treat, 115: 1-5.

78. Rebbeck, TR, Mitra, N, Domchek, SM, Wan, F, Chuai, S, Friebel, TM, Panossian, S, Spurdle, A, Chenevix-Trench, G, Singer, CF, Pfeiler, G, Neuhausen, SL, Lynch, HT, Garber, JE, Weitzel, JN, Isaacs, C, Couch, F, Narod, SA, Rubinstein, WS, Tomlinson, G, Ganz, PA, Olopade, OI, Tung, N, Blum, JL, Greenberg, R, Nathanson, KL, & Daly, MB. (2009). Modification of Ovarian Cancer Risk by BRCA1/2 Interacting Genes in a Multicenter Cohort of BRCA1/2 Mutation Carriers. Cancer Res, 69: 5801-5810. PMCID: PMC2751603.

79. Saetrom P, Biesinger J, Li SM, Smith, D, Thomas, LF, Majzoub, K, Rivas, GE, Alluin, J, Rossi, JJ, Krontiris, TG, Weitzel, JN, Daly, MB, Benson, AB, Kirkwood, JM, O'Dwyer, PJ, Sutphen, R, Stewart, JA, Johnson, D, & Larson, GP. (2009). A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis. Cancer Res, 69: 7459-7465. PMCID: PMC2747041.

80. Torres, D, Rashid, MU, Seidel-Renkert, A, Weitzel, JN, Briceno, I, & Hamann, U. (2009). Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat, 117: 679-681.

81. Antoniou, AC, Beesley, J, McGuffog, L, Sinilnikova, OM, Healey, S, Neuhausen, SL, Ding, YC, Rebbeck, TR, Weitzel, JN, Lynch, HT, Isaacs, C, Ganz, PA, Tomlinson, G, Olopade, OI, Couch, FJ, Wang, X, Lindor, NM, Pankratz, VS, Radice, P, Manoukian, S, Peissel, B, Zaffaroni, D, Barile, M, Viel, A, Allavena, A, Dall'Olio, V, Peterlongo, P, Szabo, CI, Zikan, M, Claes, K, Poppe, B, Foretova, L, Mai, PL, Greene, MH, Rennert, G, Lejbkowicz, F, Glendon, G, Ozcelik, H, Andrulis, IL, Thomassen, M, Gerdes, AM, Sunde, L, Cruger, D, Birk Jensen, U, Caligo, M, Friedman, E, Kaufman, B, Laitman, Y, Milgrom, R, Dubrovsky, M, Cohen, S, Borg, A, Jernstrom, H, Lindblom, A, Rantala, J, Stenmark-Askmalm, M, Melin, B, Nathanson, K, Domchek, S, Jakubowska, A, Lubinski, J, Huzarski, T, Osorio, A, Lasa, A, Duran, M, Tejada, MI, Godino, J, Benitez, J, Hamann, U, Kriege, M, Hoogerbrugge, N, van der Luijt, RB, van Asperen, CJ, Devilee, P, Meijers-Heijboer, EJ, Blok, MJ, Aalfs, CM, Hogervorst, F, Rookus, M, Cook, M, Oliver, C, Frost, D, Conroy, D, Evans, DG, Lalloo, F, Pichert, G, Davidson, R, Cole, T, Cook, J, Paterson, J, Hodgson, S, Morrison, PJ, Porteous, ME, Walker, L, Kennedy, MJ, Dorkins, H, Peock, S, Godwin, AK, Stoppa-Lyonnet, D, de Pauw, A, Mazoyer, S, Bonadona, V, Lasset, C, Dreyfus, H, Leroux, D, Hardouin, A, Berthet, P, Faivre, L, Loustalot, C, Noguchi, T, Sobol, H, Rouleau, E, Nogues, C, Frenay, M, Venat-Bouvet, L, Hopper, JL, Daly, MB, Terry, MB, John, EM, Buys, SS, Yassin, Y, Miron, A, Goldgar, D, Singer, CF, Dressler, AC, Gschwantler-Kaulich, D, Pfeiler, G, Hansen, TV, Jonson, L, Agnarsson, BA, Kirchhoff, T, Offit, K, Devlin, V, Dutra-Clarke, A, Piedmonte, M, Rodriguez, GC, Wakeley, K, Boggess, JF, Basil, J, Schwartz, PE, Blank, SV, Toland, AE, Montagna, M, Casella, C, Imyanitov, E, Tihomirova, L, Blanco, I, Lazaro, C, Ramus, SJ, Sucheston, L, Karlan, BY, Gross, J, Schmutzler, R, Wappenschmidt, B, Engel, C, Meindl, A, Lochmann, M, Arnold, N, Heidemann, S, Varon-Mateeva, R, Niederacher, D, Sutter, C, Deissler, H, Gadzicki, D, Preisler-Adams, S, Kast, K, Schonbuchner, I, Caldes, T, de la Hoya, M, Aittomaki, K, Nevanlinna, H, Simard, J, Spurdle, AB, Holland, H, Chen, X, Platte, R, Chenevix-Trench, G, & Easton, DF. (2010). Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res, 70: 9742-9754. PMCID: PMC2999830.

82. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Sinilnikova OM, Stoppa-Lyonnet D, Hogervorst FBL, Devilee P, Lubinski J, Jakubowska A, Spurdle A, Healey S, John EM, Hopper JL, Buys SL, Daly MB, Southey M, Terry M, Schmutzler RK, Domchek SM, Nathanson KL, Greene M, Friedman E, Andrulis I, Offit K, Borg A, Harbst K, Gerdes A, Thomassen M, Peterlongo P, Radice P, Caldes T, Singler CF, Greene MH, Guidugli L, Lindor NM, Hansen TVO, Lindblom A, Rantala J, Guillermo IB, Lazaro C, Garber J, Ramus S, Gayther S, Phelan C, Narod S, Szabo CI, Osorio A, Caligo MA, Beattie M, Hamann U, Godwin AK, Montagna M, Pasini B, Neuhausen SL, Karlan BY, Tung N, Nevanlinna H, Toland AE, Weitzel JN, Olopade O, Rubinstein W, Martin NG, Montgomery GW, Chang-Claude J, Brauch H, Severi G, Cox A, Miron P, Eccles D, Eckel-Passow J, Vachon C, Dunning A, Pharoah PPD, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF, & Couch FJ. (2010). A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet, 42: 885-892. PMCID: PMC3130795.

83. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, & Tutt A. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 376: 245-251.

84. Daly, MB, Axilbund, JE, Buys, S, Crawford, B, Farrell, CD, Friedman, S, Garber, JE, Goorha, S, Gruber, SB, Hampel, H, Kaklamani, V, Kohlmann, W, Kurian, A, Litton, J, Marcom, PK, Nussbaum, R, Offit, K, Pal, T, Pasche, B, Pilarski, R, Reiser, G, Shannon, KM, Smith, JR, Swisher, E, & Weitzel, JN. (2010). Genetic/familial high-risk assessment: Breast and ovarian. J Natl Compr Canc Netw, 8(5): 562-594.

85. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, & Rebbeck TR. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA-J Am Med Assoc, 304: 967-975. PMCID: PMC2948529.

86. Domchek, SM, Friebel, TM, Garber, JE, Isaacs, C, Matloff, E, Eeles, R, Evans, DG, Rubinstein, W, Singer, CF, Rubin, S, Lynch, HT, Daly, MB, Weitzel, JN, Ganz, PA, Pichert, G, Olopade, OI, Tomlinson, G, Tung, N, Blum, JL, Couch, F, & Rebbeck, TR. (2010). Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat, 124: 195-203. PMCID: PMC2949487.

87. Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, GEMO Study Collaborators, Hogervorst FBL, Rookus MA, Collée JM, Hoogerbrugge N, van Roozendaal KEP, HEBON Study Collaborators, Piedmonte M, Rubinstein W, Nerenstone S, Van Le L, Blank SV, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Lazaro C, Blanco I, Arason A, Johansson OT, Barkardottir RB, Devilee P, Olopade OI, Neuhausen SL, Wang X, Fredericksen ZS, Peterlongo P, Manoukian S, Barile M, Viel A, Radice P, Phelan CM, Narod S, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, OCGN, Toland AE, Montagna M, D’Andrea E, Friedman E, Laitman Y, Borg A, Beattie M, Ramus SJ, Domchek SM, Nathanson KL, Rebbeck T, Spurdle AB, Chen X, Holland H, kConFab, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Overeem Hansen TV, Nielsen FC, Greene MI, Mai PL, Osorio A, Durán M, Andres R, Benitez J, Weitzel JN, Garber J, Hamann U, Peock S, Cook M, Oliver C, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Walker L, Eason J, Barwell J, Godwin AK, Schmutzler RK, Wappenschmidt B, Engert S, Arnold N, Gadzicki D, Dean M, Gold B, Klein RJ, Couch FJ, Chenevix-Trench G, Easton DF, Daly MJ, Antoniou AC, Altshuler DM, & Offit K. (2010). Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genet, 6: e1001183. PMCID: PMC2965747.

88. Huizenga CR, Lowstuter K, Banks KC, Lagos VI, Vandergon VO, & Weitzel JN. (2010) Evolving perspectives on genetic discrimination in health insurance among health care providers. Fam Cancer, 9: 253-260.

89. Jasperson, KW, Vu, TM, Schwab, AL, Neklason, DW, Rodriguez-Bigas, MA, Burt, RW, & Weitzel, JN. (2010). Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. Fam Cancer, 9:99-107. PMCID: PMC3620042.

90. MacDonald, D, Blazer, KR, & Weitzel, JN. (2010). Extending Comprehensive Cancer Center Expertise in Clinical Cancer Genetics and Genomics to Diverse Communities: The power of partnership. J Natl Compr Canc Netw, 8: 615-624. PMCID: PMC3299537.

91. MacDonald DJ, Sarna L, Weitzel JN, & Ferrell B. (2010). Women's perceptions of the personal and family impact of genetic cancer risk assessment: Focus group findings. J Genet Couns, 19: 148-160.

92. Robson M, Storm C, Weitzel JN, Wollins D, & Offit K. (2010). American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol, 28: 893-901.

93. Stadler ZK, Thorn P, Robson ME, Weitzel JN, Gold B, Klein R, & Offit K. (2010). Genome-wide Association Studies of Cancer. J Clin Oncol, 28: 4255-4267. PMCID: PMC2953976.

94. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler R, Wardley A, Mitchell G, Earl H, Wickens M, & Carmichael J. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 376: 235-244.

95. Blazer, KR, MacDonald, DJ, Culver, JO, Huizenga, CR, Morgan, RJ, Uman, GC, & Weitzel, JN (2011). Personalized cancer genetics training for personalized medicine: Improving community-based healthcare through a genetically literate workforce. Genet Med. 13(9): 832-840. PMCID: PMC3337331

96. Brown SM, Osann KE, Culver JO, MacDonald DJ, Sand S, Thornton AA, Bowen DJ, Metcalfe KA, Burke HB, Robson ME, Grant M, & Weitzel JN. (2011). Health Literacy, Numeracy, and Interpretation of Graphical Breast Cancer Risk Estimates. Patient Educ Couns, 83: 92-98.

97. Clague J, Wilhoite G, Adamson A, Bailis A, Weitzel JN, & Neuhausen SL. (2011) RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS One, 6(9), e25632. PMCID: PMC3182241.

98. Culver JO, Macdonald DJ, Thornton AA, Sand SR, Grant M, Bowen DJ, Burke H, Garcia N, Metcalfe KA, & Weitzel JN. (2011). Development and Evaluation of a Decision Aid for BRCA Carriers with Breast Cancer. J Genet Couns, 20: 294-307. PMCID: PMC3531556.

99. Im, KM, Kirchhoff, T, Wang, X, Green, T, Chow, CY, Vijai, J, Korn, J, Gaudet, MM, Fredericksen, Z, Shane Pankratz, V, Guiducci, C, Crenshaw, A, McGuffog, L, Kartsonaki, C, Morrison, J, Healey, S, Sinilnikova, OM, Mai, PL, Greene, MH, Piedmonte, M, Rubinstein, WS, Hogervorst, FB, Rookus, MA, Collee, JM, Hoogerbrugge, N, van Asperen, CJ, Meijers-Heijboer, HE, Van Roozendaal, CE, Caldes, T, Perez-Segura, P, Jakubowska, A, Lubinski, J, Huzarski, T, Blecharz, P, Nevanlinna, H, Aittomaki, K, Lazaro, C, Blanco, I, Barkardottir, RB, Montagna, M, D'Andrea, E, Devilee, P, Olopade, OI, Neuhausen, SL, Peissel, B, Bonanni, B, Peterlongo, P, Singer, CF, Rennert, G, Lejbkowicz, F, Andrulis, IL, Glendon, G, Ozcelik, H, Toland, AE, Caligo, MA, Beattie, MS, Chan, S, Domchek, SM, Nathanson, KL, Rebbeck, TR, Phelan, C, Narod, S, John, EM, Hopper, JL, Buys, SS, Daly, MB, Southey, MC, Terry, MB, Tung, N, Hansen, TV, Osorio, A, Benitez, J, Duran, M, Weitzel, JN, Garber, J, Hamann, U, Peock, S, Cook, M, Oliver, CT, Frost, D, Platte, R, Evans, DG, Eeles, R, Izatt, L, Paterson, J, Brewer, C, Hodgson, S, Morrison, PJ, Porteous, M, Walker, L, Rogers, MT, Side, LE, Godwin, AK, Schmutzler, RK, Wappenschmidt, B, Laitman, Y, Meindl, A, Deissler, H, Varon-Mateeva, R, Preisler-Adams, S, Kast, K, Venat-Bouvet, L, Stoppa-Lyonnet, D, Chenevix-Trench, G, Easton, DF, Klein, RJ, Daly, MJ, Friedman, E, Dean, M, Clark, AG, Altshuler, DM, Antoniou, AC, Couch, FJ, Offit, K, & Gold, B. (2011). Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet, 130(5), 685-699. PMCID: PMC3196382.

100. Lagos-Jaramillo, VI, Press, MF, Ricker, CN, Dubeau, L, Mai, PL, & Weitzel, JN. (2011). Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat, 130(1): 281-289. PMCID: PMC3526343

101. Miller-Samuel S, MacDonald DJ, Weitzel JN, Santiago F, Martino MA, Namey T, Augustyn A, Mueller R, Forman A, Bradbury AR, Morris GJ. (2011) Variants of uncertain significance in breast cancer-related genes: real-world implications for a clinical conundrum. Part one: clinical genetics recommendations. Semin Oncol, 38(4):469-80. Review. PMID: 21810505.

102. Neuhausen, SL, Brummel, S, Ding, YC, Steele, L, Nathanson, KL, Domchek, SM, Rebbeck, TR, Singer, CF, Pfelier, G, Lynch, HT, Garber, JE, Couch, F, Weitzel, JN, Godwin, A, Narod, SA, Ganz, PA, Daly, MB, Isaacs, C, Olopade, OI, Tomlinson, G, Rubinstein, WS, Tung, N, Blum, J L, & Gillen, DL. (2011). Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk Among BRCA1 and BRCA2 Carriers. Cancer Epidem Biomar, 8(20): 1690-1702. PMCID: PMC3352680.

103. Rebbeck, T, Mitra, N, Domchek, SM, Wan, F, Friebel, TM, Tran, TV, Singer, CF, Tea, M-K M, Blum, JL, Tung, N, Olopade, O, Weitzel, JN, Lynch, HT, Snyder, CL, Garber, J, Antoniou, AC, Peock, S, Evans, DG, Paterson, J, Kennedy, MJ, Donaldson, A, Dorkins, H, Douglas, F (for EMBRACE), Rubinstein, WS, Daly, M, Isaacs, C, Nevanlinna, H, Couch, F, Andrulis, IL, Friedman, E, Laitman, Y, Ganz, PA, Tomlinson, G, Neuhausen, SL, Narod, S, Phelan, C, Greenburg, R, & Nathanson, KL. (2011) Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 71(17): 5792-5805. PMCID: PMC3170727.

104. Sorrell, AD, Lee, S, Stolle, C, Ellenhorn, J, Grix, A, Kaelin, WG, Jr., & Weitzel, JN. (2011). Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma. Clin Genet, 79: 539-545. PMCID: PMC2958253.

105. Spurdle M, Marquart L, McGuffog L, Healey S, Sinilnikova OM, Wan F, Chen X, Beesley J, Singer CF, Dressler A, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel JN, Lynch HT, Garber JE, Easton D, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DGR, Lalloo F, Eeles RA, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly MB, Isaacs C, Stoppa-Lyonet D, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verney-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame M, GEMO Study Collaborators, Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MGEM, van Os TA, Wijnen JT, Devilee P, Meijers-Heijboer HEJ, Blok MJ, Heikkinen T, Nevanlinna HA, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang X, Thomasson M, Domchek SM, Nathanson KL, Caligo MA, Jernstrom HCB, Liljegren A, Ehrencrona H, Karlsson P, Ganz PA, Olopade OI, Tomlinson G, Neuhausen SL, Antoniou AC, Chenevix-Trench G, & Rebbeck TR. (2011). Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidem Biomar, 20: 1032-1038. PMCID: PMC3089675.

106. Weitzel, JN, Blazer, KR, MacDonald, DJ, Culver, JO, & Offit, K. (2011) Genetics, Genomics and Cancer Risk Assessment: State of the art and future directions in the era of personalized medicine. CA-Cancer J Clin, 61(5): 327-359. PMCID: PMC3346864

107. Beamer, L., Grant, M., Espenschied, C., Blazer, K., Hampel, H., Weitzel, JN., et al. (2012). Reflex Immunohistochemistry and Microsatellite Instability Testing of Colorectal Tumors for Lynch Syndrome among US Cancer Programs and Follow-up of Abnormal Results. J Clin Oncol, 1;30(10):1058-63. PMCID: PMC3341150

108. Blazer, K. R., Christie, C., Uman, G., & Weitzel, J. N. (2012) Impact of Web-based Case Conferencing on Cancer Genetics Training Outcomes for Community-based Clinicians. J Cancer Educ, 27(2):217-225. PMCID: PMC3857095.

109. Clark CC, Weitzel JN, O'Connor TR. (2012) Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models. Molecular Cancer Therapeutics, 11:1948-1958. PMCID: PMC3551628.

110. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y,…Weitzel, JN,…Neuhausen, S.L. (2012) A non-synonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidem Biomar, 21:1362-1370. PMCID: PMC3415567.

111. Espenschied CR, MacDonald DJ, Culver JO, Sand S, Hurley K, Banks KC, Weitzel JN, Blazer KR. (2012) Closing the Loop: Action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs. J. Cancer Educ, 27(3):467-477. PMCID: PMC3540105.

112. Finkelman, B.S., Rubinstein, W.S., Friedman, S., Friebel, T. M., Dubitsky, S., Schonberger, N., Shoretz, R., Singer, C. F., Blum, J. L., Tung, N., Olopade, O.I., Weitzel, JN, Lynch, H.T., Snyder, S., Garber, J.E., Schildkraut, J., Daly, M.B., Isaacs, C., Pichert, G., Neuhausen, S.L., Couch, F.J., Van't Veer, L., Eeles, R., Bancroft, E., Evans, D.G., Ganz, P. A., Tomlinson, G.E, Narod, S.A, Matloff, E., Domchek, S.L., & Rebbeck, T. (2012). Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers. J Clin Oncol, 30(12):1321-1328. PMCID: PMC3341145.

113. Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N,…Weitzel, JN, et al. (2012) Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers? Cancer Epidem Biomar, 21(7):1089-1096. PMCID: PMC3593267.

114. Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN (2012) Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): genotype and survival. Cancer Genet 205 (1-2):34-41. PMCID: PMC3337330.

115. MacDonald DJ, Deri J, Ricker C, Perez MA, Ogaz R, Feldman N, Viveros LA, Paz B, Weitzel JN, Blazer, KR. (2012) Closing the Loop: An interactive action-research conference format for delivering updated medical information while eliciting Latina patient/family experiences and psychosocial needs post-genetic cancer risk assessment. Fam. Cancer, 11(3):449-445. PMCID: PMC3620038.

116. Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong L, Wyss O, Locke L, Means V, et al. (2012) Li-Fraumeni syndrome: Report of a clinical research workshop and creation of a research consortium. Cancer Genetics, 205(10):479-487. PMCID: PMC3593717

117. Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., et al. (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 133(3):1125-1130. PMCID: PMC3709568

118. Newhauser, W. D., Scheurer, M. E., Faupel-Badger, J. M., Clague, J., Weitzel, J., & Woods, K. V. (2012) The Future Workforce in Cancer Prevention: Advancing Discovery, Research, and Technology. Journal of Cancer Education. 27 Suppl 2:S128-35. PMCID: PMC3349779

119. Pilarski R, Patel DA, Weitzel JN, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, et al. (2012) The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLoS One, 7(5):e37891. PMCID: PMC3360659

120. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L,,…Weitzel, JN, et al. (2012) A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer Oncogene, 31(42):4559-4566. PMCID: PMC3342446.

121. Rodriguez, A. O., Llacuachaqui, M., Pardo, G. G., Royer, R., Larson, G., Weitzel, J. N., & Narod, S. A. (2012) BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol, 124, 236-243.

122. Sorrell A, Espenschied C, Wang W, Weitzel JN, Chu S, Parker P, Saldivar S, Bhatia R. (2012) Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype. Int J Clin Med, 3:607-613. PMCID: PMC3864030.

123. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, Radice P, Stoppa-Lyonnet D, Tavtigian S, et al. (2012) ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Human Mutation, 33(1):2-7. PMCID: PMC3240687.

124. Ashing-Giwa K, Rosales M, Lai L, Weitzel JN. (2013) Depressive Symptomatology in Latina Breast Cancer Survivors. Psycho-oncology, 22(4):845-853.

125. Bojesen SE, Pooley KA, Michailidou K, Jonathan Beesley, Pickett HA, Shen HC, Smart CE, Mai PL, Lawrenson K,…Weitzel, JN, et al. (2013) Multiple independent TERT variants associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 45(4):371-384. PMCID: PMC3670748

126. Couch FJ, Wang X, McGuffog L,…Weitzel, JN,…et al. (2013) Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLOS Genetics, 9(3):e1003212. PMCID: PMC3609646.

127. Culver JO, Brinkerhoff CD, Clague J, K. Y, Singh K, Sand SR, Weitzel JN. (2013) Variants of Uncertain Significance in BRCA Testing: Evaluation of Surgical Decisions, Risk Perception, and Cancer Distress. Clin. Genet. 84(5):464-472. PMCID: PMC3751990.

128. Finch A, Valentini A, Greenblatt E, …Weitzel, JN, et al. (2013) Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 99(6):1724-1728.

129. Gaudet M, Kuchenbaecker K, Vijai J,…Weitzel JN, et al. (2013) Identification of a BRCA2-specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genet. 9(3):e1003173.  PMCID: PMC3609647.

130. Laitman Y, Feng B-J, Zamir IM, Weitzel JN, Duncan P, Port D, Thirthagiri E, Teo SH, Evans DG, et al. (2013) Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Europ. J. Hum. Genet. 21(2):212-216. PMCID: PMC3548269.

131. Ortiz JA, Weitzel JN. (2013) Evidence of BRCA Gene Mutations Among Hispanics Shows Clinical Utility. The UCLA Undergraduate Science Journal. 26:50-57.

132. Segev Y, Iqbal J, Lubinski J, …Weitzel, JN, et al. (2013) The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study. Gynecol Oncol. Jul 2013;130(1):127-131.

133. Sorrell A, Espenschied C, Culver J, Weitzel JN. (2013) Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome: Current Status of Clinical Applications and Future Directions. Mol Diagn Ther. 2013;17(1):31-47. PMCID: PMC3627545.

134. Southey MC, Park DJ, Nguyen-Dumont T, …Weitzel, JN, et al. (2013) COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Research. 15(3):402. PMCID: PMC3706918.

135. Valentini A, Lubinski J, Byrski T, …Weitzel, JN, et al. (2013) The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat 142 (1):177-185. PMCID: PMC3940343.

136. Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, et al. (2013) Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. J. Clin. Oncol. 31(2):210-216. PMCID: PMC3532393

137. Nelson DE, Faupel-Badger J, Phillips S, …Weitzel, JN. 2014 [ePub ahead of print] Future Directions for Postdoctoral Training in Cancer Prevention: Insights from a Panel of Experts. Cancer Epidemiol Biomar.

138. Osorio A, Milne RL, Vaclová T, Pita G, …Weitzel, JN, et al. (2014 in press). DNA glycosylases involved in Base Excision Repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLOS Genetics.

139. Wain KE, Ellingson MS, McDonald JA, …Weitzel JN, et al. 2014 [ePub ahead of print] Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review. Genet. Med. PMCID: PMC Journal - In Process.

140. Wood ME, Kadlubek P, …Weitzel JN, et al. (2014) Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol 32(8):824-829.

Clinical Trials

Locations

  • City of Hope - Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010